PR and ER are key prognostic biomarkers, defining hormone-positive breast cancer and its response toward systemic hormonal therapy and/or innovative target therapy as cyclin-dependent kinase 4/6 inhibitors [56,57,58]. Here, ESR1 is linked to breast carcinoma.